دورية أكاديمية
أعرض في EDS

Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study.

التفاصيل البيبلوغرافية
العنوان: Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study.
المؤلفون: Niwaha AJ; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK.; NCD Theme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda., Rodgers LR; Institute of Health Research, University of Exeter Medical School, Exeter, UK., Carr ALJ; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK., Balungi PA; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK.; NCD Theme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda., Mwebaze R; Department of Medicine, St. Francis Hospital Nsambya, Kampala, Uganda., Hattersley AT; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK.; Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., Shields BM; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK., Nyirenda MJ; NCD Theme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.; NCD Epidemiology, London School of Hygiene & Tropical Medicine, London, UK., Jones AG; Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter Medical School, Exeter, UK Angus.Jones@exeter.ac.uk.; Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
المصدر: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2022 Apr; Vol. 10 (2).
نوع المنشور: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Published by BMJ in partnership with the American Diabetes Association Country of Publication: England NLM ID: 101641391 Publication Model: Print Cited Medium: Internet ISSN: 2052-4897 (Electronic) Linking ISSN: 20524897 NLM ISO Abbreviation: BMJ Open Diabetes Res Care Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Published by BMJ in partnership with the American Diabetes Association
مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/drug therapy , Hypoglycemia*/chemically induced , Hypoglycemia*/epidemiology , Metformin*/adverse effects, Blood Glucose ; Blood Glucose Self-Monitoring/methods ; Glycated Hemoglobin/analysis ; Humans ; Insulin/adverse effects ; Insulin, Regular, Human ; Sulfonylurea Compounds/adverse effects
مستخلص: Introduction: People living with diabetes in low-resource settings may be at increased hypoglycemia risk due to food insecurity and limited access to glucose monitoring. We aimed to assess hypoglycemia risk associated with sulphonylurea (SU) and insulin therapy in people living with type 2 diabetes in a low-resource sub-Saharan African setting.
Research Design and Methods: This study was conducted in the outpatients' diabetes clinics of two hospitals (one rural and one urban) in Uganda. We used blinded continuous glucose monitoring (CGM) and self-report to compare hypoglycemia rates and duration in 179 type 2 diabetes patients treated with sulphonylureas (n=100) and insulin (n=51) in comparison with those treated with metformin only (n=28). CGM-assessed hypoglycemia was defined as minutes per week below 3mmol/L (54mg/dL) and number of hypoglycemic events below 3.0 mmol/L (54 mg/dL) for at least 15 minutes.
Results: CGM recorded hypoglycemia was infrequent in SU-treated participants and did not differ from metformin: median minutes/week of glucose <3 mmol/L were 39.2, 17.0 and 127.5 for metformin, sulphonylurea and insulin, respectively (metformin vs sulphonylurea, p=0.6). Hypoglycemia risk was strongly related to glycated haemoglobin (HbA1c) and fasting glucose, with most episodes occurring in those with tight glycemic control. After adjusting for HbA1c, time <3 mmol/L was 2.1 (95% CI 0.9 to 4.7) and 5.5 (95% CI 2.4 to 12.6) times greater with sulphonylurea and insulin, respectively, than metformin alone.
Conclusions: In a low-resource sub-Saharan African setting, hypoglycemia is infrequent among people with type 2 diabetes receiving sulphonylurea treatment, and the modest excess occurs predominantly in those with tight glycemic control.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
References: Diabetes Res Clin Pract. 2015 Aug;109(2):226-32. (PMID: 26003888)
BMC Med Res Methodol. 2018 Jun 22;18(1):63. (PMID: 29929477)
BMJ Open Diabetes Res Care. 2021 Sep;9(1):. (PMID: 34535465)
Diabetes Care. 2010 Jun;33(6):1297-9. (PMID: 20215454)
Diabetes Obes Metab. 2019 Jul;21(7):1585-1595. (PMID: 30843327)
Can J Diabetes. 2014 Feb;38(1):38-44. (PMID: 24485212)
Diabet Med. 2012 Mar;29(3):293-302. (PMID: 21838763)
Diabetes Ther. 2020 Jan;11(1):15-35. (PMID: 31773420)
BMC Endocr Disord. 2020 Mar 10;20(1):35. (PMID: 32151247)
Diabetes Care. 2017 Dec;40(12):1631-1640. (PMID: 29162583)
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667. (PMID: 28688818)
BMJ. 2000 Aug 12;321(7258):405-12. (PMID: 10938048)
CMAJ Open. 2014 Jul 22;2(3):E162-75. (PMID: 25295236)
Diabetes Care. 2019 Jan;42(Suppl 1):S61-S70. (PMID: 30559232)
Diabetes Care. 2009 Jul;32(7):1188-93. (PMID: 19389816)
J Diabetes Complications. 2006 Nov-Dec;20(6):395-401. (PMID: 17070446)
Ann Intern Med. 2018 Apr 17;168(8):569-576. (PMID: 29507945)
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):132-157. (PMID: 29535952)
Lancet Diabetes Endocrinol. 2018 Oct;6(10):798-808. (PMID: 30170949)
BMC Endocr Disord. 2019 Jan 30;19(1):17. (PMID: 30700277)
PLoS One. 2015 Jun 10;10(6):e0126427. (PMID: 26061690)
Diabetes Obes Metab. 2018 Feb;20(2):427-437. (PMID: 28834075)
Diabetes Obes Metab. 2016 Sep;18(9):907-15. (PMID: 27161418)
Diabetologia. 2020 Apr;63(4):711-721. (PMID: 31901950)
Diabetes Res Clin Pract. 2020 Dec;170:108522. (PMID: 33096187)
N Engl J Med. 2018 Aug 16;379(7):633-644. (PMID: 30110583)
معلومات مُعتمدة: United Kingdom DH_ Department of Health
فهرسة مساهمة: Keywords: CGM; Developing Countries; Diabetes Mellitus, Type 2; Hypoglycemia
المشرفين على المادة: 0 (Blood Glucose)
0 (Glycated Hemoglobin A)
0 (Insulin)
0 (Insulin, Regular, Human)
0 (Sulfonylurea Compounds)
9100L32L2N (Metformin)
تواريخ الأحداث: Date Created: 20220422 Date Completed: 20220425 Latest Revision: 20221207
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9024213
DOI: 10.1136/bmjdrc-2021-002714
PMID: 35450869
قاعدة البيانات: MEDLINE
الوصف
تدمد:2052-4897
DOI:10.1136/bmjdrc-2021-002714